Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2015

View Archived Issues

New antibiotic effective against Gram-positive bacteria without detectable resistance

CEO presents development activity at BioMarin Pharmaceutical

New data on the effect of PennVax-B in HIV-1-infected adults

Vonapanitase induces vasodilatation in human atherosclerotic arteries

Depomed to acquire U.S. rights to NuCynta franchise

Merck Sharp & Dohme to study MK-8291 in patients with post-herpetic neuralgia with allodynia

Regado Biosciences and Tobira Therapeutics to create NASH company

Researchers present data on the diagnostic utility of [11C]PBB-3-based PET imaging

Active Biotech discusses pipeline outlook

DT-01 enhances HCC treatment antitumor activity in animal models

New phase II data for mipsagargin reported

Novel NS5B inhibitors disclosed by Merck & Co. for HCV

AbbVie divulges novel BTK inhibitors

Merck KGaA patents novel FSH-R modulators for infertility

Pfizer discloses new dopamine D1 receptor ligands

Forendo Pharma presents novel 17beta-HSD1 inhibitors

European Commission approves Novartis' Cosentyx in plaque psoriasis

Addex and Dystonia Medical Research Foundation to explore dipraglurant for dystonia

FDA grants fast track designation to deflazacort for Duchenne muscular dystrophy

FDA removes partial clinical hold on aldoxorubicin trials

Invion reports interim data from phase II trial of oral INV-102 in smoking cessation

Richter and Actavis report phase III results for cariprazine in schizophrenia

Oncore Biopharma merges with Tekmira Pharmaceuticals

BeiGene reports development of kinase inhibitors for cancer

Janssen researchers prepare TLR7 agonists

Laboratoire Biodim tests novel agents for HIV

Tiziana Life Sciences licenses milciclib from Nerviano Medical Sciences

Tobira initiates phase I study of cenicriviroc and pioglitazone

Verastem's VS-5584 awarded European orphan drug designation, begins new trial

BioInvent's BI-1206 to enter collaborative phase I/II trial

Qu Biologics initiates phase IIa trial of QBKPN SSI in NSCLC

Hybrigenics initiates phase II study of inecalcitol for CML

Eleison and Intelgen partner on Chinese development of inhaled lipid-complexed cisplatin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...